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oston, Massachusetts
OBJECTIVES We aimed to determine whether intensive statin therapy reduces hospitalization for heart
failure (HF) in high-risk patients.
BACKGROUND While the relationship between intensive statin therapy and ischemic events is well
established, its relationship to the risk of HF after an acute coronary syndrome (ACS) is not
well defined.
METHODS The Pravastatin or Atorvastatin Evaluation and Infection Trial–Thrombolysis In Myocardial
Infarction 22 (PROVE IT–TIMI 22) study randomized 4,162 patients, stabilized after ACS,
to either intensive statin therapy (atorvastatin 80 mg) or moderate statin therapy (pravastatin
40 mg). Hospitalization for HF occurring more than 30 days after randomization was
determined during a mean follow-up of 24 months. B-type natriuretic peptide (BNP) levels
were measured at baseline (median seven days after randomization).
RESULTS Treatment with atorvastatin 80 mg significantly reduced the rate of hospitalization for HF
(1.6% vs. 3.1%, hazard ratio [HR] 0.55, 95% confidence interval [CI] 0.35 to 0.85, p 
0.008) independently of a recurrent myocardial infarction or prior history of HF. The risk of
HF increased steadily with increasing quartiles of BNP (HR 2.6, 95% CI 1.2 to 5.5, p 
0.016 for the highest quartile compared with the lowest). Among patients with elevated levels
of BNP (80 pg/ml), treatment with atorvastatin significantly reduced the risk of HF
compared with pravastatin (HR 0.32, 95% CI 0.13 to 0.8, p 0.014). A meta-analysis of four
trials that included 27,546 patients demonstrates a 27% reduction in the odds of hospital-
ization for HF with intensive statin therapy.
CONCLUSIONS Intensive statin therapy reduces the risk of hospitalization for HF after ACS with the most
gain in patients with elevated levels of BNP. (J Am Coll Cardiol 2006;47:2326–31) © 2006
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.03.034by the American College of Cardiology Foundation
r
s
m
i
i
d
T
p
t
a
o
M
T
T
I
(
A
S
p
a
tipid-lowering therapy, and in particular intensive statin
herapy, reduces the risk of death and recurrent ischemia in
atients hospitalized for an acute coronary syndrome (ACS)
1) and in patients with chronic coronary artery disease
2,3). The relationship between statin therapy and conges-
ive heart failure (HF) is less well described with some
nvestigators raising theoretical concerns that statins could
orsen HF. For example, in one study, low cholesterol
evels were associated with worse outcomes among patients
ith HF (4) while another study suggested that statins, via
nhibition of the mitochondrial enzyme ubiquinone, may
ecrease myocardial contraction (5). Trials that compared
oderate dose statin therapy versus placebo in stable pa-
ients have reported conflicting results with some showing a
enefit of statin therapy (6) while others have not (7–10).
he primary reports from trials of intensive statin therapy
uggest that higher doses of statin may reduce rates of
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nd editing of this manuscript.m
Manuscript received January 25, 2006; revised manuscript received March 8, 2006,
ccepted March 16, 2006.ehospitalization for HF when compared with moderate
tatin therapy, but there are few details (2,3,11).
Heart failure is an important cause of morbidity and
ortality in patients with ACS and is gaining in relative
mportance as effective therapies reduce the risk of recurrent
schemia (12,13). Identifying those patients at high risk for
eveloping HF after ACS is clearly of clinical importance.
he use of biomarkers, in particular B-type natriuretic
eptide (BNP) (14,15), has improved the clinician’s ability
o identify patients who are at high risk of death or HF after
n ACS. However, the influence of intensive statin therapy
n this risk is unknown.
ETHODS
he Pravastatin or Atorvastatin Evaluation and Infection
rial–Thrombolysis In Myocardial Infarction 22 (PROVE
T–TIMI 22) study has been reported in detail previously
1,16). This trial enrolled 4,162 patients hospitalized for
CS—either acute myocardial infarction (with or without
T-segment elevation) or high-risk unstable angina—in the
receding 10 days. Eligible patients were in stable condition
nd had a total cholesterol level within the first 24 h after
he onset of the index event that was 240 mg/dl (6.21
mol/l), or200 mg/dl (5.18 mmol/l) if they were on prior
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June 6, 2006:2326–31 Intensive Statin Therapy and HF in ACSipid-lowering therapy. Patients were ineligible for the study
f they had a co-existing condition that shortened expected
urvival to 2 years, had undergone percutaneous coronary
ntervention within the previous six months (other than for
he qualifying event), or coronary artery bypass surgery
ithin the previous two months, or were scheduled to
ndergo bypass surgery in response to the index event.
tudy protocol. The protocol specified that patients were
o receive standard medical and interventional treatment for
CS. Eligible patients were randomly assigned in a 1:1 ratio
o receive 40 mg of pravastatin or 80 mg of atorvastatin daily
n a double-blind, double-dummy fashion. Patients were
een for follow-up visits at 30 days, 4 months, and every 4
onths thereafter until their final visit. Plasma samples
ncluded in this analysis were obtained at baseline in 3,752
atients, and measurements were made in a core facility
Brigham and Women’s Hospital, Boston, Massachusetts).
validated assay for BNP (ADVIA Centaur BNP, Bayer
ealthcare Diagnostics, Tarrytown, New York) was used,
nd concentrations were evaluated as quartiles: BNP 15
g/ml (n  1,032) for quartile 1, BNP 16 to 32 pg/ml (n 
67) for quartile 2, BNP 33 to 65 pg/ml (n  928) for
uartile 3, and BNP65 pg/ml (n 925) for quartile 4 and
ith the cut-point of 80 pg/ml (17).
nd points. Heart failure was defined by the need for
ospitalization for the condition. The primary efficacy
utcome for this analysis was the time from randomization
o the first occurrence of hospitalization for congestive HF
hat occurred 30 days or longer after randomization. Myo-
ardial infarction was defined by the presence of symptoms
uggestive of ischemia or infarction, with either electrocar-
iographic evidence (new Q waves in two or more leads) or
ardiac-marker evidence of infarction (1,16).
tatistical analysis. All analyses are based on the intention-
o-treat principle. Cumulative event curves of hospitalization
or HF derived from Kaplan-Meier estimates are presented.
stimates of the hazard ratios (HRs) and associated 95%
onfidence intervals (CIs) comparing pravastatin with ator-
astatin were obtained with a Cox proportional hazards
odel with randomized treatment as the covariate. For
nalyses including BNP, cumulative event curves of hospi-
alization for HF derived from Kaplan-Meier estimates are
resented along with the HR from a Cox proportional
azards model that included age, gender, diabetes, hyper-
ension, body mass index, creatinine, index diagnosis, and
ercutaneous coronary intervention during the index event.
We performed a meta-analysis of four large randomized
Abbreviations and Acronyms
ACS  acute coronary syndrome
BNP  B-type natriuretic peptide
CI  confidence interval
HR  hazard ratio
OR  odds ratiorials that compared an intensive versus moderate statin therapy in high-risk cardiac patients: the PROVE IT–
IMI 22 trial that compared 40 mg of pravastatin versus 80
g of atorvastatin in patients stabilized after ACS (1); the
reating to New Targets (TNT) trial that compared 10
ersus 80 mg of atorvastatin in patients with stable coronary
isease (2); the A to Z trial that compared 20 versus 80 mg
f simvastatin in ACS patients (11); and the Incremental
ecrease in Clinical End Points Through Aggressive Lipid
owering (IDEAL) trial that compared 20 mg of simva-
tatin versus 80 mg of atorvastatin in patients with a history
f myocardial infarction (3). Summary data on the rates of
ongestive HF were abstracted from the publications of the
ther trials. Odds ratios (ORs) and 95% CIs for the effect of
ntensive statin therapy versus moderate statin therapy on
he incidence of HF were calculated for each trial. The
esults from trials were combined using a random-effects
odel that used weighting based on inverse variance.
etween-trial heterogeneity was assessed. All statistical
nalyses were performed using Stata/SE, version 9.1 (Stata-
orp. LP, College Station, Texas).
ESULTS
enefit of intensive statin therapy of HF. This analysis
ncluded all 4,162 patients enrolled in the PROVE IT–
IMI 22 study. As previously described, patients were
nrolled a median of seven days after onset of their index
vent, and there were no differences between treatment
roups in terms of age, gender, index diagnosis, or rates of
rior myocardial infarction, revascularization, diabetes, or
ypertension (1). There were also no differences in the rate
f prior HF between treatment arms (3.2% for atorvastatin
s. 3.5% for pravastatin, p  NS), the rate of ST-segment
levation myocardial infarction (33.4% vs. 35.6%, p  NS),
r the rate of revascularization for the index event (69.1% vs.
8.7%, p  NS).
Treatment with atorvastatin 80 mg was associated with a
ignificant 45% reduction in the rate of hospitalization for
F (1.6% vs. 3.1% [HR 0.55, 95% CI 0.35 to 0.85, p 
.008]) (Fig. 1). This reduction in the risk of HF was not
ttenuated when controlling for recurrent myocardial infarc-
ion (HR 0.58, 95% CI 0.37 to 0.90, p 0.016) or a history
f prior HF (HR 0.55, 95% CI 0.35 to 0.86, p  0.008).
he benefit of atorvastatin 80 mg was similar after exclud-
ng all patients (n  36) who developed HF after having
uffered a recurrent myocardial infarction or recurrent isch-
mia requiring hospitalization or revascularization (HR
.47, 95% CI 0.26 to 0.86, p  0.015). The benefit of
ntensive statin therapy was also similar when the first 30
ays after randomization were included in the analysis (HR
.53, 95% CI 0.35 to 0.80, p  0.002).
NP and the risk of HF. Compared with those without
ubsequent hospitalization for HF, patients who developed
F had higher baseline levels of BNP (median 58 vs. 31
g/ml, p  0.001) and were more likely to have a concen-
ration of BNP 80 pg/ml (41.2% vs. 23.2%, p  0.001).
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Intensive Statin Therapy and HF in ACS June 6, 2006:2326–31he concentration of BNP showed a significant graded
elationship with the risk of HF, with a significantly higher
isk of HF among patients in the highest (BNP65 pg/ml)
ompared with the lowest quartile (BNP 15 pg/ml,
djusted HR 2.6, 95% CI 1.2 to 5.5, p  0.016).
ntensive statin therapy and BNP. There was no differ-
nce in baseline levels of BNP between treatment arms (31
s. 32 ng/l, p  NS). When examined by elevated (80
g/ml) or normal (80 pg/ml) baseline levels of BNP and
reatment arm, patients with elevated baseline levels (80
g/ml) of BNP randomized to pravastatin had the highest
ate of hospitalization for HF (6.9%) followed by those
atients with normal BNP randomized to pravastatin
2.3%), patients with an elevated BNP randomized to
igure 1. Cumulative incidence of the hospitalization for congestive hea
oderate statin therapy with pravastatin 40 mg, reduced the risk for hospit
nterval 0.35 to 0.85, p  0.008). This benefit was not attenuated after con
igure 2. Cumulative incidence of hospitalization for congestive heart fail
atriuretic peptide (BNP) (80 ng/l) on atorvastatin; 2) patients with norm
torvastatin; and 4) patients with elevated BNP on pravastatin. Compariso
ncluded age, gender, diabetes mellitus, hypertension, smoking, body mas
vent. Among patients with elevated levels of BNP, treatment with atorvas
onfidence interval (CI) 3.3 to 14.4, p  0.001 compared with BNP 80
80/atorvastatin; ***HR 1.7, 95% CI 0.90 to 3.4, p  0.099 compared with BN
ith BNP 80/pravastatin.torvastatin (2.2%), and then patients normal baseline levels
f BNP randomized to atorvastatin were at 1.2% (Fig. 2).
ssignment to atorvastatin significantly reduced the risk of
he development of HF among patients with elevated levels
f BNP (HR 0.32, 95% CI 0.13 to 0.8, p  0.014).
lthough patients with such elevated levels of BNP had a
reater absolute reduction in the risk of HF (4.7%, HR
.29, 95% CI 0.11 to 0.73, p  0.009) with intensive statin
herapy than patients with low BNP (1.1%, HR 0.56, 95%
I 0.29 to 1.1, p  0.09), formal statistical testing for an
nteraction of BNP with the effect of treatment was not
ignificant (p interaction  0.32).
eta-analysis of intensive statin therapy trials. A meta-
nalysis of the four published large, randomized trials
ure. Intensive statin therapy with atorvastatin 80 mg, as compared with
ion for congestive heart failure by 45% (hazard ratio 0.55, 95% confidence
g for recurrent myocardial infarction (MI) or prior history of heart failure.
ratified into four groups: 1) patients with normal baseline levels of B-type
NP on pravastatin; 3) patients with elevated levels of BNP (80 ng/l) on
ween groups were performed using a Cox proportional hazard model that
ex, creatinine, index event, percutaneous coronary intervention for index
ignificantly reduced the risk of heart failure. *Hazard ratio (HR) 6.9, 95%
vastatin; **HR 2.2, 95% CI 0.85 to 5.9, p  0.115 compared with BNPrt failure st
al B
ns bet
s ind
tatin s
/atorP 80/atorvastatin; †HR 0.32, 95% CI 0.13 to 0.8, p  0.014 compared
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June 6, 2006:2326–31 Intensive Statin Therapy and HF in ACShat compared intensive statin therapy with moderate
tatin therapy and that reported the rates of congestive
F demonstrates a highly significant 27% reduction in
he odds of hospitalization for HF in (n  27,546, OR
.73, 95% CI 0.63 to 0.84, p  0.001) (chi-square for
eterogeneity  2.25 [degrees of freedom  3], p 
.523) (Fig. 3).
ISCUSSION
mong patients hospitalized for an ACS, treatment with
ntensive statin therapy significantly reduced the subsequent
evelopment of HF requiring hospitalization. This benefit
as independent of recurrent infarction suggesting that
ntensive statin therapy lowers the risk of HF independently
f its ability to reduce recurrent ischemic injury. As antici-
ated, baseline levels of BNP in patients with ACS were
trongly associated with the risk of future HF. However,
mong patients with elevated levels of BNP (80 pg/ml),
reatment with intensive statin therapy (atorvastatin 80 mg)
ignificantly reduced the risk of HF compared with mod-
rate statin therapy (pravastatin 40 mg); the absolute risk of
evelopment of HF in patients with such elevated levels of
NP was reduced by 4.7% by intensive statin therapy (47
ospitalizations for HF prevented per 1,000 patients
reated).
Our findings, both from the PROVE IT–TIMI 22 study
nd from the other large randomized trials, reveal a consis-
ent benefit of intensive statin therapy in reducing episodes
f HF by 27% among more than 27,000 patients who had
low baseline incidence of prior HF. The benefit observed
n the PROVE IT–TIMI 22 study was directionally,
hough not statistically, greater than the benefit seen in the
ther trials (2,3,11). This trend may be because this trial was
omprised of a post-ACS population that received imme-
iate intensive statin therapy, as opposed to the A to Z trial,
igure 3. Benefit of intensive statin therapy versus moderate statin therapy
nalysis includes the Pravastatin or Atorvastatin Evaluation and Infection Trial
reating to New Targets (TNT) (2), A to Z (11), and Incremental Decrease innother post-ACS trial, in which intensive statin therapy
ith simvastatin 80 mg was not started until one month
fter randomization. In comparison with the Scandinavian
imvastatin Survival Study (4S) trial in which a benefit of
oderate dose simvastatin on HF was not observed until
hree years of therapy (6), the benefit of intensive statin
herapy in the PROVE IT–TIMI 22 study was demon-
trated at two years, with an early separation of the event
urves for hospitalization for HF.
To determine whether the benefit of intensive statin
herapy in reducing the occurrence of HF was due to a
echanism other than the reduction of recurrent infarction,
e controlled both for the rate of recurrent infarction as well
s excluded all patients who suffered a recurrent infarction.
he benefit of intensive statin therapy was consistent in
oth of these analyses, suggesting that statins act to reduce
ew onset HF via pathways other than by reducing new
yocardial necrosis.
There are several proposed mechanisms by which statin
herapy, and in particular intensive statin therapy, may
educe the rate of HF. These proposed pathways include
otential “pleiotropic” actions of statins, such as decreases in
oth Ras and Rho protein production via blockade of the
evalonate pathway, which, in turn, prevents cell prolifer-
tion and hypertrophy (Ras) (18) and increases nitric oxide
roduction (Rho) (18,19). These effects may, in turn,
mprove vascular function and potentially enhance ventric-
lar function. A small randomized trial, for example, dem-
nstrated improved ventricular function with one-year of
herapy with 20 mg of atorvastatin compared with placebo
n patients with non-ischemic cardiomyopathy (20). This
nding may provide a mechanistic explanation to the
mproved outcomes associated with statin therapy observed
n several retrospective studies of patients with chronic HF
21–23).
ducing the risk of hospitalization for heart failure in 27,546 patients. Thisin re
–Thrombolysis In Myocardial Infarction 22 (PROVE IT–TIMI 22) (1),
End Points Through Aggressive Lipid Lowering (IDEAL) (3) studies.
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Intensive Statin Therapy and HF in ACS June 6, 2006:2326–31The effect of statins on circulating markers of inflamma-
ion in patients with HF has resulted in conflicting results.
everal studies in patients with HF have shown that statins
educe biomarkers such as C-reactive protein, endothelin-1
24), and tumor necrosis factor-alpha (22). On the other
and, another study that compared atorvastatin 80 mg to
lacebo did not demonstrate any change in levels of inflam-
atory, hemostatic, or neurohormonal markers after 12
eeks of intense statin therapy (25). The apparent discrep-
ncy in findings may be due to the relative severity of HF in
he different studies (the majority of the patients in the
egative trial were in class II failure [25] while in the other
tudies they were class III or IV) and in the duration of
herapy (24,26). Studies with longer follow-up are needed
o resolve the important questions concerning potential
echanisms of beneficial action seen with statin therapy.
Identifying patients at high risk for developing HF after
CS is clearly of clinical importance. Several reports have
ow shown that elevated baseline concentrations of BNP
re associated with the development of HF after an ACS
14,15). As confirmed in this analysis, measurement of BNP
t the time of the index hospitalization is a powerful tool for
isk stratification in order to identify patients at high risk for
eveloping HF. The value of biomarkers in clinical practice
ests on both improved risk assessment and guidance of
herapy. We found that these results highlight the utility of
NP in identifying patients in whom the affect of intensive
tatin therapy produced the greatest benefit. Even among
atients treated with atorvastatin, elevated levels of BNP
till tended to confer an increased, although attenuated, risk
f hospitalization for HF.
tudy limitations. There are several potential limitations
f this analysis. The end point of hospitalization for HF was
pre-specified secondary end point of the PROVE IT–
IMI 22 study and was chosen in order to identify more
erious presentations of HF. It may then underestimate the
rue incidence of HF in this population as milder states of
F may be treated as an outpatient and may also explain the
elatively low overall event rates. Despite this, the treatment
ffect of intensive statin therapy was readily observed.
onclusions. In addition to the proven benefit of inten-
ive statin therapy in reducing recurrent ischemic events,
his analysis demonstrates the ability of intensive statin
herapy to lower the risk of the development of HF
ndependently of the reduction in ischemic events. Trials
f intensive statins in patients with known HF are
ngoing. Results from these studies, in particular among
atients with non-ischemic cardiomyopathy, will provide
urther insight into whether statins improve outcome
ndependently of reducing ischemia and potentially iden-
ify a new therapy for these patients. In the meantime,
he reduction in HF associated with intensive statin
herapy observed in the PROVE IT–TIMI 22 study and
he other trials of intensive statin therapy further empha-
ize the clinical importance of aggressive statin therapy in
1atients at high risk for cardiovascular complications of
CS and chronic coronary artery disease.
eprint requests and correspondence: Dr. Benjamin M. Scirica,
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assachusetts 02115. E-mail: bscirica@partners.org.
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